This bill matters because it changes how Medicare can buy prescription drugs, directly impacting both drug makers and potentially the cost of medicines for patients. Current law allows Medicare to negotiate prices for some expensive drugs, but this bill carves out an exception for a specific group: small biotech companies that pour a lot of money into developing new treatments.
If this bill passes, these R&D-intensive small biotechs would be shielded from Medicare's price negotiations for their limited number of drugs, starting in 2029. Supporters believe this protection is crucial for fostering innovation, allowing these companies to take risks and fund the development of new, potentially life-saving medicines. If the bill does not pass, these companies' drugs would eventually be subject to price negotiations, which could mean reduced revenues and potentially impact their capacity to invest in cutting-edge research.
KEY PROVISIONS
5AI-extracted
PROVISION 01
Establishes an exception for research and development-intensive small biotech manufacturers from the Medicare drug price negotiation program.
Shields certain small companies' drugs from government price controls, potentially impacting drug development and costs.
PROVISION 02
Defines a 'small biotech manufacturer' as a company with 5 or fewer qualifying drugs and not controlled by certain foreign governments.
Sets specific criteria to ensure the exception targets particular types of domestic companies.
PROVISION 03
Requires 'R&D-intensive' companies to invest an 'applicable percent' (30-70% based on drug count) of their past three years' net revenue into research and development.
Ensures the exception is granted only to companies genuinely committed to significant research and innovation.
PROVISION 04
States that a drug loses its exception if the qualifying small manufacturer is acquired by a non-qualifying manufacturer after 2029.
Prevents larger companies from using the exception after acquiring a small biotech, maintaining the intended focus of the exemption.
PROVISION 05
Requires manufacturers to submit annual applications with financial data and creates a process for them to appeal denied eligibility.
Establishes a system for oversight and fairness in determining which companies qualify for the exception.
This bill matters because it changes how Medicare can buy prescription drugs, directly impacting both drug makers and potentially the cost of medicines for patients. Current law allows Medicare to negotiate prices for some expensive drugs, but this bill carves out an exception for a specific group: small biotech companies that pour a lot of money into developing new treatments.
If this bill passes, these R&D-intensive small biotechs would be shielded from Medicare's price negotiations for their limited number of drugs, starting in 2029. Supporters believe this protection is crucial for fostering innovation, allowing these companies to take risks and fund the development of new, potentially life-saving medicines. If the bill does not pass, these companies' drugs would eventually be subject to price negotiations, which could mean reduced revenues and potentially impact their capacity to invest in cutting-edge research.
KEY PROVISIONS
AI-extracted
high
Establishes an exception for research and development-intensive small biotech manufacturers from the Medicare drug price negotiation program.
Shields certain small companies' drugs from government price controls, potentially impacting drug development and costs.
med
Defines a 'small biotech manufacturer' as a company with 5 or fewer qualifying drugs and not controlled by certain foreign governments.
Sets specific criteria to ensure the exception targets particular types of domestic companies.
high
Requires 'R&D-intensive' companies to invest an 'applicable percent' (30-70% based on drug count) of their past three years' net revenue into research and development.
Ensures the exception is granted only to companies genuinely committed to significant research and innovation.
med
States that a drug loses its exception if the qualifying small manufacturer is acquired by a non-qualifying manufacturer after 2029.
Prevents larger companies from using the exception after acquiring a small biotech, maintaining the intended focus of the exemption.
med
Requires manufacturers to submit annual applications with financial data and creates a process for them to appeal denied eligibility.
Establishes a system for oversight and fairness in determining which companies qualify for the exception.
Exception for initial price applicability years begins
After 2029
Acquisition clause effective date (applies to acquisitions after this time)
Not later than the selected drug publication date for the relevant initial price applicability year
Dispute resolution process for a manufacturer must conclude
GLOSSARY
AI-written
Medicare drug price negotiation program
A government program established by law that allows Medicare to bargain with drug companies for lower prices on certain prescription medications.
Qualifying single source drug
A prescription drug that has no generic or competing biosimilar versions available and meets other specific criteria, making it eligible for potential price negotiation under Medicare.
Small biotech manufacturer
A drug company that has five or fewer qualifying drugs and is not owned by or controlled by certain foreign governments.
Research and development-intensive
Describes a company that invests a significant portion of its past revenues (based on a defined percentage) into discovering and developing new drugs and medical treatments.
Net revenue
The total income a company receives from selling its products, after accounting for any returns, allowances, and discounts.
Initial price applicability year
The first year in which a new negotiated price for a specific drug would go into effect under the Medicare program.
Social Security Act
ACTION TIMELINE
2 EVENTS
JUN 3, 25
Introduced in Senate
INTROREFERRAL
JUN 3, 25
Read twice and referred to the Committee on Finance.
